GlassScriptPhysician profile
Eric S Francis
NPI 1467599746
$1,696.58
in general payments reported to CMS, 2019-2025
25 companies · $1,312 in 2025
The $1,312 reported for 2025 was more than what 90% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $21.85 · 2021: $83.65 · 2023: $17.78 · 2024: $262 · 2025: $1,312.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,591.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,591.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $214.48 | 2025 | |
| Lilly USA, LLC | $188.94 | 2024-2025 | Mounjaro, Zepbound, Jardiance |
| Glaxosmithkline, LLC. | $170.89 | 2024-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Novo Nordisk INC | $157.69 | 2025 | Rybelsus, Ozempic, Wegovy |
| Exact Sciences Corporation | $110.98 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Medtronic, INC. | $98.85 | 2021-2024 | Intellis Adaptivestim |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $84.75 | 2025 | Xifaxan, Relistor |
| Antares Pharma, INC. | $78.24 | 2024-2025 | Xyosted |
| Amgen INC. | $56.93 | 2024-2025 | Evenity, Prolia |
| Pfizer INC. | $56.38 | 2025 | |
| Abbott Laboratories | $56.08 | 2025 | Freestyle Libre 3 |
| Teva Pharmaceuticals USA, INC. | $52.47 | 2025 | Austedo Xr |
| Xeris Pharmaceuticals, INC. | $41.65 | 2024-2025 | Keveyis |
| Averitas Pharma INC. | $39.78 | 2025 | Qutenza |
| Esperion Therapeutics, INC. | $38.24 | 2024-2025 | Nexletol |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $33.11 | 2024-2025 | Dexcom G6 Transmitter |
| Globus Medical, INC. | $32.44 | 2025 | Senza |
| Phathom Pharmaceuticals, INC. | $32.17 | 2025 | Voquezna |
| Astrazeneca Pharmaceuticals LP | $30.30 | 2024-2025 | Farxiga, Airsupra |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $26.63 | 2025 | Caplyta |
| Abbvie INC. | $23.03 | 2025 | |
| Acclarent, INC | $21.85 | 2019 | |
| Sumitomo Pharma America, INC. | $19.88 | 2025 | Gemtesa |
| Novartis Pharmaceuticals Corporation | $15.53 | 2025 | |
| Si-Bone, INC. | $15.29 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Francis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.